Astria Therapeutics (NASDAQ:ATXS) Now Covered by JMP Securities

JMP Securities assumed coverage on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report sent to investors on Friday, MarketBeat.com reports. The firm issued an outperform rating and a $26.00 target price on the biotechnology company’s stock.

A number of other research analysts have also issued reports on ATXS. Oppenheimer upped their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.67.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $7.86 on Friday. Astria Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $16.90. The business has a 50-day simple moving average of $8.93 and a two-hundred day simple moving average of $10.45.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently made changes to their positions in ATXS. FMR LLC increased its holdings in Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Astria Therapeutics in the 3rd quarter valued at $3,423,000. Cubist Systematic Strategies LLC acquired a new position in Astria Therapeutics during the 2nd quarter worth about $2,561,000. Finally, Millennium Management LLC boosted its holdings in Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after acquiring an additional 218,518 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.